Questions?

Request a Medical Science Liaison (MSL)

Questions?

Request a Medical Science Liaison (MSL)

Treat Early With UPTRAVI1

UPTRAVI (selexipag) is a prostacyclin pathway therapy that is structurally distinct from prostacyclin1

A selective mechanism of action1

Three established 
prostanoid 
receptors in 
the human pulmonary artery2

In animal studies*

UPTRAVI is the only prostacyclin pathway agent to selectively target the IP receptor5

The only established relaxant prostanoid receptor in the human pulmonary artery2

Learn more about UPTRAVI

VIEW GRIPHON TRIAL

*The 2022 ESC/ERS Guidelines recommend adding UPTRAVI for patients without cardiopulmonary comorbidities who are at intermediate-low risk despite receiving ERA/PDE5i therapy. In these patients, switching from a PDE5i to riociguat may be considered. In patients who present as intermediate-high or high risk on oral therapies, also consider adding UPTRAVI or switching from a PDE5i to riociguat if it is not feasible to add IV or SC prostacyclin analogs.

*Clinical significance in humans is unknown.

GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensION; IP=prostacyclin.

References: 1. UPTRAVI (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal. 2007;7:1359-1374. 3. Capra V, Bäck M, Angiolillo DJ, et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost. 2014;12(2):126-137. 4. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9-21. 5. Zeng C, Liu J, Zheng X, et al. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension. Respir Res. 2023;24(1):263. doi:10.1186/s12931-023-02559-3